125 related articles for article (PubMed ID: 2669140)
1. Intraperitoneal cisplatin chemotherapy in the management of ovarian carcinoma.
Markman M
Semin Oncol; 1989 Aug; 16(4 Suppl 6):79-82. PubMed ID: 2669140
[TBL] [Abstract][Full Text] [Related]
2. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer.
Markman M; Reichman B; Hakes T; Rubin S; Lewis JL; Jones W; Barakat R; Curtin J; Almadrones L; Hoskins W
Gynecol Oncol; 1993 Jul; 50(1):100-4. PubMed ID: 8349150
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study.
Feun LG; Blessing JA; Major FJ; DiSaia PJ; Alvarez RD; Berek JS
Gynecol Oncol; 1998 Dec; 71(3):410-5. PubMed ID: 9887240
[TBL] [Abstract][Full Text] [Related]
4. Current status of intraperitoneal therapy for ovarian cancer.
Markman M
Curr Opin Obstet Gynecol; 1993 Feb; 5(1):99-104. PubMed ID: 7678757
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
6. Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a Phase II Gynecologic Oncology Group trial.
Braly PS; Berek JS; Blessing JA; Homesley HD; Averette H
Gynecol Oncol; 1995 Feb; 56(2):164-8. PubMed ID: 7896179
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
[TBL] [Abstract][Full Text] [Related]
8. Ovarian carcinoma: the role of chemotherapy.
Thigpen JT; Vance RB; Lambuth BW
Semin Oncol; 1988 Jun; 15(3 Suppl 3):16-23. PubMed ID: 3293214
[TBL] [Abstract][Full Text] [Related]
9. Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the iv route.
Casper ES; Kelsen DP; Alcock NW; Lewis JL
Cancer Treat Rep; 1983 Mar; 67(3):235-8. PubMed ID: 6682012
[TBL] [Abstract][Full Text] [Related]
10. Intraperitoneal therapy of ovarian cancer.
Markman M
Semin Oncol; 1998 Jun; 25(3):356-60. PubMed ID: 9633848
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal cisplatin and carboplatin in the management of ovarian cancer.
Markman M
Semin Oncol; 1994 Apr; 21(2 Suppl 2):17-9; quiz 20, 58. PubMed ID: 8202717
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal chemotherapy as treatment for ovarian carcinoma and gastrointestinal malignancies: the Memorial Sloan-Kettering Cancer Center experience).
Markman M; Reichman B; Hakes T; Hoskins W; Rubin S; Jones W; Lewis JL
Acta Med Austriaca; 1989; 16(3-4):65-7. PubMed ID: 2609915
[TBL] [Abstract][Full Text] [Related]
13. Consolidation intraperitoneal chemotherapy in epithelial ovarian cancer patients following negative second-look laparotomy.
Tarraza HM; Boyce CR; Smith WG; Jones MA
Gynecol Oncol; 1993 Sep; 50(3):287-90. PubMed ID: 8406188
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal Therapy of Ovarian Cancer.
Markman M
Oncologist; 1996; 1(1 & 2):18-21. PubMed ID: 10387964
[TBL] [Abstract][Full Text] [Related]
15. Salvage therapy in ovarian cancer: is there a role for intraperitoneal drug delivery?
Markman M
Gynecol Oncol; 1993 Oct; 51(1):86-9. PubMed ID: 8244180
[TBL] [Abstract][Full Text] [Related]
16. An update on the use of intraperitoneal chemotherapy in the management of ovarian cancer.
Markman M
Cancer J; 2009; 15(2):105-9. PubMed ID: 19390303
[TBL] [Abstract][Full Text] [Related]
17. [Intraperitoneal chemotherapy in ovarian carcinoma].
Piura B
Harefuah; 2001 Sep; 140(9):844-9, 894, 893. PubMed ID: 11579736
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
Makhija S; Sabbatini P; Aghajanian C; Venkatraman E; Spriggs DR; Barakat R
Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
[TBL] [Abstract][Full Text] [Related]
19. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.
Shapiro F; Schneider J; Markman M; Reichman BS; Venkatraman E; Barakat R; Almadrones L; Spriggs D
Gynecol Oncol; 1997 Oct; 67(1):39-45. PubMed ID: 9345354
[TBL] [Abstract][Full Text] [Related]
20. The role of paclitaxel in the management of coelomic epithelial carcinoma of the ovary: a review with emphasis on the Gynecologic Oncology Group experience.
Thigpen T; Vance RB; McGuire WP; Hoskins WJ; Brady M
Semin Oncol; 1995 Dec; 22(6 Suppl 14):23-31. PubMed ID: 8553080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
